Aarti Drugs Ltd Share Price

Technical Analysis Aarti Drugs

The stock

is showing a short-term recovery trend after forming a base near ₹325–350. It has gradually formed higher lows and is currently trading around ₹431 indicating improving buying interest. However the stock is now approaching an important resistance zone so a breakout confirmation is needed for further upside. Support & Resistance immediate support is around ₹415–405 followed by stronger support near ₹390–375. On the upside ₹435–450 is the immediate resistance zone. A sustained close above ₹450 with strong volume can strengthen the bullish setup and open the way towards ₹475–500. Short-Term Outlook: The setup is cautiously bullish while the stock remains above ₹405–415. Buyers can consider fresh entry on a decisive breakout above ₹450 or on a controlled pullback towards support. Existing holders can continue to hold with a trailing stop-loss below ₹405. A close below ₹390 would weaken the current recovery structure.

See More

Aarti Drugs: Diversified Portfolio Supports Growth Prospects

Aarti Drugs continues to strengthen its position in the pharmaceutical and specialty chemicals segment, supported by a diversified product portfolio and established manufacturing capabilities. The company operates across APIs, formulations, specialty chemicals and pharmaceutical intermediates, serving both domestic and international markets. Focus on product development, capacity expansion and operational efficiency remains important for sustaining growth. Export opportunities and increasing demand for pharmaceutical ingredients can provide additional avenues, while raw-material prices, regulatory requirements, pricing pressure and global market conditions remain key factors to monitor. Continued investment in manufacturing capabilities and a broader product mix could help the company strengthen its competitive position over the longer term. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes ***** must verify information before investing and consider their financial position & risk profile. please read full disclosure disclaimer in given link visit website www dot investmentcure dot com *****

See More

Aarti Drugs and Aarti Pharmalabs both reported strong financial updates this week.

Aarti Drugs and Aarti Pharmalabs both reported strong financial updates this week. Aarti Drugs posted a 19% YoY revenue growth in Q1 FY27 with major capacity expansion plans, while Aarti Pharmalabs announced Q4 FY26 results showing revenue growth but a sharp decline in profit margins. Additionally, Aarti Pharmalabs approved a ₹149 crore capex for new manufacturing capacity. 📊 Latest Updates on Aarti Pharma Companies 🔹 Aarti Drugs Ltd (Q1 FY27 – June 2026) Consolidated Revenue: ₹703.6 crore (+19% YoY) EBITDA: ₹96.9 crore (+30% YoY) PAT: ₹50.1 crore (adjusted growth ~29% YoY excluding tax refund) Domestic Revenue Growth: +25% Export Revenue Growth: +12% Specialty Chemicals: Sales surged 149% to ₹82 crore, driven by the new Sayakha plant. Capacity Expansion Plans: Metformin capacity to scale from 1,400 tons/month → 2,200 tons/month (new USFDA-approved block). Methyl salicylate derivatives capacity planned at 350–400 tons/month. Margins: EBITDA margin expanded to 13.8%, targeting 15% in coming quarters. 🔹 Aarti Pharmalabs Ltd (Q4 FY26 – March 2026) Total Revenue: ₹582.64 crore (+3.35% YoY) Operating Profit: ₹101.97 crore (-16.97% YoY) Net Profit (PAT): ₹61.12 crore (-30.81% YoY) Operating Margin: 17.5% (down 19.66% YoY) EPS: ₹6.74 (down from ₹7.20 YoY) Stock Movement (10 Aug 2026): BSE: ₹821.45 (+20%) NSE: ₹800 (+16.64%) Trend: Technical analysis suggests reversal of bullish momentum; short-term outlook bearish. 🔹 Aarti Pharmalabs Ltd (Q1 FY27 – June 2026) Consolidated Revenue: ₹536 crore (+38.7% YoY) Consolidated PAT: ₹76.14 crore (+65.3% YoY) Standalone PAT: ₹71.31 crore (+49.4% YoY) Capex Approval: ₹149 crore for new intermediate manufacturing block (to serve CDMO customers). Leadership Changes: Effective October 1, 2026.

See More

Update for investors of

s is currently trading at Rs. 361.90, up by 4.35 points or 1.22% from its previous closing of Rs. 357.55 on the BSE. The scrip opened at Rs. 356.95 and has touched a high and low of Rs. 362.95 and Rs. 350.05 respectively. So far 6606 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 574.95 on 21-Jul-2025 and a 52 week low of Rs. 312.50 on 07-Apr-2025. Last one week high and low of the scrip stood at Rs. 375.00 and Rs. 342.65 respectively. The current market cap of the company is Rs. 3303.06 crore. The promoters holding in the company stood at 55.03%, while Institutions and Non-Institutions held 12.27% and 32.70% respectively. Aarti Drugs’ subsidiary -- Pinnacle Chile SpA, has incorporated an overseas wholly owned subsidiary in the name of Tripharma Chile SpA. Accordingly, the newly incorporated company becomes a step-down subsidiary of the Aarti Drugs. The new subsidiary is incorporated for marketing the formulation drugs and participating in tender and private market in Chile. Its business is in line with the business of its holding companies. Aarti Drugs is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science.

See More